MISAA, LLC commenced FDA process for patent pending, tacrolimus enhanced lateral flow assay

TORRANCE, Calif., Feb. 13, 2024 /PRNewswire/ — MISAA and IOS are pleased to announce they have commenced the FDA certification process for the patent pending, tacrolimus immunosuppressant in vitro diagnostic, Tac-Assay. MISAA, LLC. (www.misaallc.com), a subsidiary of Intelligent Optical…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks